Market News

Why Alaunos Therapeutics (NASDAQ:TCRT) Collapsed 50% on Thursday

Shares of Alaunos Therapeutics (NASDAQ:TCRT) collapsed more than 50% halfway through today’s trading session. The fall in price might be attributable to a unfavorable update that was released regarding a patient in the company’s TCR-T cell therapy trial.

Nevertheless, investors who got into the stock at the beginning of the year are still up almost 200% on a year-to-date basis. In addition, Alaunos is set to report early study data at a scientific conference later on in the third quarter.


Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More